We are live on ! Find out more
LTRN icon

Lantern Pharma

26 hedge funds and large institutions have $6.84M invested in Lantern Pharma in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

137% more capital inflows, than outflows

Capital inflows: $197K | Capital outflows: $83K

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

0.17% more ownership

Funds ownership: 13.1% → 13.27% (+0.17%)

0% more funds holding

Funds holding: 26 → 26 (0)

62% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 13

82% less call options, than puts

Call options by funds: $55K | Put options by funds: $311K

Holders
26
Holders Change
–
Holders Change %
0%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
13
Closed
2
Calls
$55​K
Puts
$311​K
Net Calls
-⁠$256​K
Net Calls Change
-⁠$240​K

LTRN Hedge Fund Activity: Q3 2022 in Review

26 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q3 2022, worth a combined $6.84M — down 15% from $8.06M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new LTRN positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 13 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $78.3K. The largest seller was Osaic Holdings, cutting an estimated $13.4K.

  • 26 institutional investors held Lantern Pharma (LTRN) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $6.84M of Lantern Pharma stock for Q3 2022, down 15% quarter-over-quarter.
  • 3 funds opened new Lantern Pharma positions in Q3 2022 and 2 closed out, a net change of +1 holder.
  • The largest Lantern Pharma buyer in Q3 2022 was Susquehanna International Group, an estimated $78.3K added.
  • The largest Lantern Pharma seller in Q3 2022 was Osaic Holdings, an estimated $13.4K sold.

Based on aggregated 13F filings for Q3 2022.